IsoPlexis Toekomstige groei
Future criteriumcontroles 2/6
IsoPlexis is forecast to grow earnings and revenue by 43.9% and 42.1% per annum respectively. EPS is expected to grow by 46% per annum. Return on equity is forecast to be -50.9% in 3 years.
Belangrijke informatie
43.9%
Groei van de winst
46.0%
Groei van de winst per aandeel
| Life Sciences winstgroei | 18.4% |
| Inkomstengroei | 42.1% |
| Toekomstig rendement op eigen vermogen | -50.9% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 21 Mar 2023 |
Recente toekomstige groei-updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2025 | 72 | -28 | N/A | N/A | 1 |
| 12/31/2024 | 49 | -46 | N/A | N/A | 2 |
| 12/31/2023 | 30 | -56 | N/A | N/A | 2 |
| 12/31/2022 | 17 | -106 | -104 | -97 | N/A |
| 9/30/2022 | 19 | -98 | -118 | -109 | N/A |
| 6/30/2022 | 19 | -104 | -125 | -117 | N/A |
| 3/31/2022 | 19 | -102 | -132 | -104 | N/A |
| 12/31/2021 | 17 | -92 | -111 | -87 | N/A |
| 9/30/2021 | 15 | -76 | -90 | -67 | N/A |
| 6/30/2021 | 14 | -59 | -70 | -47 | N/A |
| 3/31/2021 | 12 | -41 | -33 | -31 | N/A |
| 12/31/2020 | 10 | -29 | -25 | -22 | N/A |
| 12/31/2019 | 8 | -15 | -17 | -15 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: ISO is forecast to remain unprofitable over the next 3 years.
Winst versus markt: ISO is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: ISO is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: ISO's revenue (42.1% per year) is forecast to grow faster than the US market (8.1% per year).
Hoge groei-inkomsten: ISO's revenue (42.1% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: ISO is forecast to be unprofitable in 3 years.